发明名称 |
FGFR4 Promotes Cancer Cell Resistance in Response to Chemotherapeutic Drugs |
摘要 |
The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR4 gene are determined in a patient suffering from a hyperproliferative disorder, e.g. cancer. Based on the results of this determination and the status of the disorder to be treated a therapeutic protocol may be developed. Yet another subject of the present invention is a screening method. |
申请公布号 |
US2010143386(A1) |
申请公布日期 |
2010.06.10 |
申请号 |
US20070513413 |
申请日期 |
2007.11.02 |
申请人 |
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN, E. V. |
发明人 |
ULLRICH AXEL;BERGER HANS-JUERGEN;ROIDL ANDREAS |
分类号 |
A61K39/395;A61K31/407;A61K31/675;A61K31/704;A61K31/7048;A61K31/7088;A61K38/02;A61P35/00;C12N15/11;C12N15/113;G01N33/53;G01N33/566 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|